The next generation of weight-loss drugs is just around the corner. Hundreds of weight-loss medications are in various stages of development. While oral and injectable weight-loss medications such as Ozempic or Wegovy can be an effective short-term strategy, the long-term success and safety are still being researched and are unknown.
How Will These Drugs Differ?
Dozens of companies like Pfizer, Bayer, and Amgen are developing drugs and trying to acquire drugs that are either a once-a-month injectable or a more convenient pill. These would differ from the injectable options currently available, which require people to use them once a week.
Many of the most promising drugs in development target GLP-1 receptors, similar to Ozempic and Wegovy, but may also mimic other hormones that impact satiety and metabolism.
Ozempic, Wegovy, Zepbound and Mounjaro all work by imitating the GLP-1 hormone, which is made in the small intestine. GLP-1 based injectables help lower blood sugar, reduce food intake, and promote a feeling of fullness and satiety. Mounjaro and Zepbound also target the GIP receptor, which stimulates satiety in the hypothalamus.
NYBG is keeping a close eye on changes. Dedicated providers are here to answer any questions patients may have to best support their weight-loss decisions.
NYBG is Here to Guide You on Your Weight-Loss Journey
According to the World Health Organization more than one billion people globally suffer from obesity. Obesity is linked to a variety of health problems including:
- Type 2 diabetes
- High blood pressure
- Increase risk of heart disease
- High cholesterol
- Sleep apnea
- Joint pain
Losing weight can help alleviate many of these health conditions.
With more weight-loss medications in production, determining the right path may become more confusing. NYBG is here to help. They work with patients to determine th